BioLife Solutions (NASDAQ:BLFS) Lowered to “Sell” at BidaskClub

BidaskClub cut shares of BioLife Solutions (NASDAQ:BLFS) from a hold rating to a sell rating in a report published on Saturday morning, BidAskClub reports.

Several other research firms have also commented on BLFS. Maxim Group set a $24.00 price target on shares of BioLife Solutions and gave the company a buy rating in a report on Wednesday, May 22nd. Zacks Investment Research lowered shares of ExlService from a hold rating to a sell rating in a report on Wednesday. ValuEngine upgraded shares of XCel Brands from a sell rating to a hold rating in a report on Tuesday, July 9th. Finally, Northland Securities boosted their price target on shares of Paycom Software from $215.00 to $275.00 and gave the company an outperform rating in a report on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $17.80.

NASDAQ:BLFS opened at $16.93 on Friday. BioLife Solutions has a one year low of $9.15 and a one year high of $26.35. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.99 and a current ratio of 14.50. The company has a market cap of $318.27 million, a price-to-earnings ratio of 120.93 and a beta of 1.31. The firm has a 50-day simple moving average of $17.22.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Thursday, May 9th. The medical equipment provider reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. BioLife Solutions had a net margin of 17.01% and a return on equity of 10.32%. The business had revenue of $5.77 million during the quarter, compared to analyst estimates of $5.67 million. Sell-side analysts expect that BioLife Solutions will post 0.12 EPS for the current fiscal year.

In other news, CEO Michael Rice sold 7,088 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $16.94, for a total value of $120,070.72. Following the transaction, the chief executive officer now owns 182,102 shares of the company’s stock, valued at approximately $3,084,807.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Walter Villiger sold 39,883 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $19.18, for a total transaction of $764,955.94. The disclosure for this sale can be found here. In the last ninety days, insiders sold 216,871 shares of company stock worth $3,826,019. Insiders own 27.00% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Cowen Prime Services LLC purchased a new position in shares of BioLife Solutions in the 1st quarter worth approximately $63,000. Signaturefd LLC purchased a new position in shares of BioLife Solutions in the 1st quarter worth approximately $161,000. GSA Capital Partners LLP grew its position in shares of BioLife Solutions by 21.1% in the 4th quarter. GSA Capital Partners LLP now owns 13,800 shares of the medical equipment provider’s stock worth $166,000 after buying an additional 2,400 shares during the last quarter. Conestoga Capital Advisors LLC purchased a new position in shares of BioLife Solutions in the 1st quarter worth approximately $238,000. Finally, Weiss Multi Strategy Advisers LLC purchased a new position in shares of BioLife Solutions in the 4th quarter worth approximately $241,000. 45.76% of the stock is currently owned by hedge funds and other institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Recommended Story: Why is the LIBOR significant?

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.